0
X4 Pharmaceuticals, Inc. Banner Image

X4 Pharmaceuticals, Inc. has reached its limit for free report views

Work for X4 Pharmaceuticals, Inc.? Upgrade Your Profile and unlock all your annual reports.

X4 Pharmaceuticals, Inc.

  • Ticker XFOR
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
X4 Pharmaceuticals, Inc. Logo Image
  • 51-200 Employees
  • Based in Cambridge, Massachusetts
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The Company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokineMore receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenström’s macroglobulinemia, and as monotherapy in patients with Severe Congenital Neutropenia. X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is discovering and developing additional product candidates.
X4 Pharmaceuticals, Inc.

Most Recent Annual Report

X4 Pharmaceuticals, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. X4 Pharmaceuticals, Inc. has reached its limit for free report views.